Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Changes in the AML treatment landscape

Richard Stone • 18 Mar 2018
EBMT 2018
Acute Myeloid Leukemia Leukemia Antibodies CPX-351 Enasidenib Gemtuzumab ozogamicin Midostaurin

Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in acute myeloid leukemia (AML), including recent drug approvals after numerous years of testing and our increasing understanding of the pathophysiology of this disease. This interview took place at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, in Lisbon, Portugal.

More from Richard Stone

2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023
2:31
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Richard Stone • 21 Mar 2023
1:14
The potential of uproleselan in patients with AML
Richard Stone • 21 Mar 2023
1:57
Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapy
Richard Stone • 21 Mar 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals